JNJ

192.13

-0.88%↓

ABT

127.78

-1.34%↓

MDT

95.86

-0.14%↓

VEEV

289.87

+1.52%↑

A

145.91

+2.06%↑

JNJ

192.13

-0.88%↓

ABT

127.78

-1.34%↓

MDT

95.86

-0.14%↓

VEEV

289.87

+1.52%↑

A

145.91

+2.06%↑

JNJ

192.13

-0.88%↓

ABT

127.78

-1.34%↓

MDT

95.86

-0.14%↓

VEEV

289.87

+1.52%↑

A

145.91

+2.06%↑

JNJ

192.13

-0.88%↓

ABT

127.78

-1.34%↓

MDT

95.86

-0.14%↓

VEEV

289.87

+1.52%↑

A

145.91

+2.06%↑

JNJ

192.13

-0.88%↓

ABT

127.78

-1.34%↓

MDT

95.86

-0.14%↓

VEEV

289.87

+1.52%↑

A

145.91

+2.06%↑

Search

BioMarin Pharmaceutical Inc

Cerrado

SectorSalud

53.7 1.28

Resumen

Variación precio

24h

Actual

Mínimo

52.5

Máximo

53.96

Métricas clave

By Trading Economics

Ingresos

241M

426M

Ventas

80M

825M

P/B

Media del Sector

15.472

36.442

BPA

1.44

Margen de beneficio

51.637

Empleados

3,040

EBITDA

95M

319M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+84.66% upside

Dividendos

By Dow Jones

Próximas Ganancias

28 oct 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-1.5B

10B

Apertura anterior

52.42

Cierre anterior

53.7

Noticias sobre sentimiento de mercado

By Acuity

25%

75%

46 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

BioMarin Pharmaceutical Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

21 oct 2025, 23:55 UTC

Acciones populares

Stocks to Watch: DraftKings, Texas Instruments, Intuitive Surgical, Pegasystems

21 oct 2025, 23:49 UTC

Ganancias

Texas Instruments Warns of Slower Semiconductor Industry Recovery -- Update

21 oct 2025, 21:40 UTC

Ganancias

Waste Connections 3Q Revenue Rises

21 oct 2025, 21:14 UTC

Ganancias
Principales Movimientos del Mercado

Intuitive Surgical 3Q Profit, Sales Jump, Sees Higher da Vinci Procedure Growth -- Update

21 oct 2025, 21:05 UTC

Adquisiciones, fusiones, absorciones

GE Vernova to Acquire Full Stake in Prolec GE Joint Venture

21 oct 2025, 20:57 UTC

Adquisiciones, fusiones, absorciones

DraftKings to Launch Prediction Markets Platform

21 oct 2025, 20:38 UTC

Ganancias

Intuitive Surgical 3Q Profit, Sales Jump, Sees Higher da Vinci Procedure Growth

21 oct 2025, 20:35 UTC

Ganancias

Capital One 3Q Sales, Profit Jump

21 oct 2025, 20:32 UTC

Ganancias

Texas Instruments 3Q Revenue Up on Growth Across End Markets

21 oct 2025, 23:44 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

21 oct 2025, 23:44 UTC

Charlas de Mercado

Nikkei May Rise on Weaker Yen, Hopes for Takaichi's Econ Steps -- Market Talk

21 oct 2025, 23:39 UTC

Charlas de Mercado

Gold Consolidates; May Undergo Further Technical Correction -- Market Talk

21 oct 2025, 23:36 UTC

Charlas de Mercado

BHP Has Hidden Leverage to Gold's Rush -- Market Talk

21 oct 2025, 22:55 UTC

Adquisiciones, fusiones, absorciones

Scentre Says This Forms Part of Capital Management Strategy

21 oct 2025, 22:55 UTC

Adquisiciones, fusiones, absorciones

Scentre: Continues to Evaluate Strategic Opportunities Including New JV Partners

21 oct 2025, 22:54 UTC

Adquisiciones, fusiones, absorciones

Scentre Notes Media Report on Possible Sale of Stake in Westfield Chermside to Dexus Fund

21 oct 2025, 21:09 UTC

Charlas de Mercado
Ganancias

Netflix Creators Have Started Using AI in Production -- Market Talk

21 oct 2025, 20:58 UTC

Charlas de Mercado
Ganancias

Netflix Aims to Build on 'KPop Demon Hunters' Mania -- Market Talk

21 oct 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

21 oct 2025, 20:50 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Financial Services Roundup: Market Talk

21 oct 2025, 20:43 UTC

Ganancias

Netflix Stock Drops After Earnings Miss Estimates -- Barrons.com

21 oct 2025, 20:41 UTC

Ganancias

Dow Industrials Hit Record, Boosted by Strong Earnings -- WSJ

21 oct 2025, 20:33 UTC

Adquisiciones, fusiones, absorciones

GE Vernova: Deal Accelerates Growth for Electrification Segment >GEV

21 oct 2025, 20:33 UTC

Adquisiciones, fusiones, absorciones

GE Vernova Acquiring Remaining 50% Stake of JV From Xignux >GEV

21 oct 2025, 20:32 UTC

Adquisiciones, fusiones, absorciones

GE Vernova: Prolec GE Expects Low Double-Digit Rev Growth in Coming Years >GEV

21 oct 2025, 20:32 UTC

Adquisiciones, fusiones, absorciones

GE Vernova: Prolec GE Expects $3B in Rev at 25% Adj EBITDA Margin in 2025 >GEV

21 oct 2025, 20:32 UTC

Adquisiciones, fusiones, absorciones

GE Vernova: $5.275B Purchase Price at Closing, Expected to Be Funded Equally With Cash & Debt >GEV

21 oct 2025, 20:32 UTC

Adquisiciones, fusiones, absorciones

GE Vernova Will Acquire Remaining 50% Stake of Prolec GE >GEV

21 oct 2025, 20:31 UTC

Adquisiciones, fusiones, absorciones

GE Vernova To Fully Acquire Prolec GE Joint Venture >GEV

21 oct 2025, 20:29 UTC

Ganancias

Northrop Stock Tumbles on Sales Disappointment. When Good Isn't Good Enough. -- Barrons.com

Comparación entre iguales

Cambio de precio

BioMarin Pharmaceutical Inc Esperado

Precio Objetivo

By TipRanks

84.66% repunte

Estimación a 12 meses

Media 98 USD  84.66%

Máximo 122 USD

Mínimo 60 USD

De acuerdo con 22 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para BioMarin Pharmaceutical Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

22 ratings

18

Comprar

4

Mantener

0

Vender

Puntuación técnica

By Trading Central

59.405 / 62.19Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Very Strong Bearish Evidence

Largo Plazo

Weak Bearish Evidence

Sentimiento

By Acuity

46 / 371 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation. The company was incorporated in 1996 and is headquartered in San Rafael, California.
help-icon Live chat